XML 37 R23.htm IDEA: XBRL DOCUMENT v3.26.1
OTHER OPERATING EXPENSES, NET
 6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
OTHER OPERATING EXPENSES, NET OTHER OPERATING EXPENSES, NET
Other operating expenses, net for the six months ended June 30, 2026 and 2025 are summarized below (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Divestiture-related expenses$5,931 $— $5,931 $— 
Contingent consideration charges (gains)1,663 (357)(614)(3,032)
Acquisition-related expenses— 991 — 2,502 
Legal settlement— — — 7,000 
Total other operating expenses, net$7,594 $634 $5,317 $6,470 
Divestiture-Related Expenses
The Company recognized divestiture-related expenses of $5.9 million during the three and six months ended June 30, 2026, primarily related to third-party services and legal fees associated with divesting iovera° to Zimmer. For more information, see Note 3, Assets and Liabilities Held for Sale.
Flexion Acquisition Contingent Consideration
The Company recognized contingent consideration charges of $1.7 million and gains of $0.6 million during the three and six months ended June 30, 2026, respectively. The Company recognized contingent consideration gains of $0.4 million and $3.0 million during the three and six months ended June 30, 2025, respectively. See Note 11, Financial Instruments, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration and more information regarding the changes in fair value.
Acquisition-Related Expenses
The Company recognized acquisition-related expenses of $1.0 million and $2.5 million during the three and six months ended June 30, 2025, respectively, primarily related to third-party services and legal fees associated with the GQ Bio Acquisition.
Legal Settlement
The Company recognized $7.0 million of costs during the six months ended June 30, 2025 related to the patent infringement suits against the eVenus ANDA Filers (as defined below). For more information, see Note 17, Commitments and Contingencies.